List of Excipients in Branded Drug MIGERGOT

Generic Drugs Containing MIGERGOT

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	ergotamine tartrate and caffeine	0713-0166	HARD FAT
Cosette Pharmaceuticals Inc	ergotamine tartrate and caffeine	0713-0166	TARTARIC ACID
Horizon Pharma Inc	ergotamine tartrate and caffeine	75987-090	FAT, HARD
Horizon Pharma Inc	ergotamine tartrate and caffeine	75987-090	TARTARIC ACID

What are the Most Frequently-Used Excipients in MIGERGOT?

# Of NDCs	Excipient
1	FAT, HARD
1	HARD FAT
2	TARTARIC ACID

Migergot Excipient Strategy and Commercial Opportunities in Ergotamine-Caffeine Suppositories

Last updated: August 22, 2026

Migergot is a rectal suppository containing ergotamine tartrate 2 mg and caffeine 100 mg for the acute treatment of migraine attacks. Its commercial opportunity is driven less by active-ingredient innovation than by dosage-form performance, excipient control, manufacturing reliability, and access to an underrepresented rectal migraine product category. The principal development opportunities are a robust suppository base, improved storage stability, reduced leakage and mess, better patient handling, and a regulatory strategy aligned with an abbreviated or 505(b)(2) pathway.

What is Migergot and how is it formulated?

Migergot combines ergotamine tartrate, a vasoconstrictive ergot alkaloid, with caffeine in a rectal suppository. The labeled strength is 2 mg of ergotamine tartrate and 100 mg of caffeine per suppository.[1]

Attribute	Migergot
Active ingredients	Ergotamine tartrate and caffeine
Strength	2 mg / 100 mg per rectal suppository
Dosage form	Rectal suppository
Therapeutic category	Acute migraine treatment
Original regulatory pathway	Legacy NDA product
Biologic or small molecule	Small molecule
Primary formulation issue	Delivery of a low-dose, potent drug combination from a lipid or semisolid rectal base
Main commercial barrier	Market access, manufacturing economics, and limited category demand rather than biologic complexity

The rectal route has a functional rationale. Migraine attacks may involve nausea and vomiting, which can reduce the practicality of oral treatment. A suppository can provide an alternative route when oral administration is difficult. The dosage form also creates formulation constraints involving melting behavior, drug distribution, content uniformity, microbial control, packaging, and patient acceptability.

Public labeling and standard drug references identify the active ingredients and the dosage form, but excipient details should be controlled through the current approved labeling, supplier specifications, and the approved chemistry, manufacturing, and controls record.[1,2]

What excipients are most important for Migergot suppositories?

The highest-value excipient decisions involve the suppository base, wetting and dispersion behavior, antioxidant protection, and packaging compatibility.

Suppository base

A lipid-based base is the most commercially logical starting point for a Migergot-equivalent product because it can soften or melt at or near physiological temperature and support drug release after rectal administration. Candidate base systems include:

• Hard fat or hydrogenated vegetable triglycerides
• Cocoa-butter-derived systems
• Semi-synthetic triglyceride bases
• Polyethylene glycol bases
• Combination lipid and hydrophilic bases

A hard-fat base may offer better patient comfort and a more familiar manufacturing platform than a high-polyethylene-glycol formulation. Polyethylene glycol systems can provide higher melting points and better resistance to warm-weather deformation, but they may produce greater local osmotic effects and can be less comfortable for some patients.

The base must be selected against the following performance targets:

1. Complete or near-complete drug release within the intended rectal residence period.
2. Uniform ergotamine and caffeine distribution in every unit.
3. Adequate mechanical strength during molding, packaging, shipping, and handling.
4. Controlled softening or melting at body temperature.
5. Minimal leakage after administration.
6. Low interaction with the active ingredients during long-term storage.

Drug dispersion and content uniformity

Ergotamine tartrate is a potent active ingredient present at a low dose. Content uniformity is therefore a major technical risk. Caffeine is present at a substantially higher dose and may have different particle-size, density, and wetting characteristics.

A suspension suppository may be more practical than a fully dissolved system, depending on the selected base. That approach requires control of:

• Particle-size distribution
• Sedimentation during filling
• Mixing time and temperature
• Viscosity during mold filling
• Agitation during the full filling cycle
• Assay and content uniformity across beginning, middle, and end-of-run units

A dissolved system can simplify content uniformity but may create solubility and crystallization risks. A suspension system can reduce solubility dependence but increases process sensitivity. The preferred strategy is a formulation with a narrow and reproducible particle-size distribution, validated mixing conditions, and a manufacturing hold time that prevents sedimentation.

Antioxidants and chelating agents

Ergot alkaloids can be sensitive to degradation pathways associated with light, oxygen, heat, and formulation microenvironment. An antioxidant may improve stability if justified by forced-degradation and real-time stability data. Possible approaches include tocopherol-based antioxidants or other pharmaceutically accepted stabilizers compatible with the selected base.

Antioxidants should not be added solely as a standard formulation practice. The development program should establish:

• The relevant degradation products
• The oxygen sensitivity of each active ingredient
• The impact of antioxidant concentration on assay and impurities
• Compatibility with the suppository base
• Potential effects on odor, color, and patient acceptability

A chelating agent may be useful if trace metals accelerate degradation, but the commercial benefit depends on demonstrated impurity control. Each added excipient increases the regulatory and supply-chain burden.

Preservatives

A conventional anhydrous lipid suppository may not require a preservative if the formulation and manufacturing process prevent microbial growth and the product is appropriately packaged. A water-containing system would face a greater preservative and microbiological-control burden.

Avoiding water can simplify:

• Microbial risk management
• Preservative qualification
• Long-term stability
• Container-closure compatibility
• Manufacturing validation

The tradeoff is that an anhydrous formulation may have more demanding drug-dispersion and physical-stability requirements.

What formulation patents could protect a Migergot product?

A formulation patent would be more defensible if it claims a measurable technical advantage rather than the use of a conventional suppository base alone. Potential claim areas include:

Base composition claims

Claims could cover a defined range of hard fat, semisynthetic triglycerides, polyethylene glycol, or mixed-base components. Patent value would depend on whether the composition produces a meaningful improvement in melting point, release, mechanical strength, or stability.

Release-profile claims

A product could be protected by claims directed to a specified percentage of ergotamine and caffeine released within a defined time under a validated in vitro rectal dissolution method. Such claims require a reliable and discriminatory test method.

Stability claims

Potential protection could target:

• Reduced ergotamine degradation
• Lower total related substances after storage
• Improved stability under elevated temperature
• Improved light stability
• Reduced polymorphic or crystallization changes

Manufacturing-process claims

Process claims could cover:

• Controlled suspension preparation
• Drug pre-dispersion
• Specific cooling rates
• Agitation during filling
• Low-shear incorporation
• Nitrogen or oxygen-controlled processing
• Defined fill-temperature windows

Packaging claims

Packaging technology may support patent protection when it materially improves product performance. Relevant approaches include unit-dose foil packaging, oxygen-barrier films, light-protective structures, and packaging that limits deformation during distribution.

A patent estate based only on common excipients is likely to be weak. A stronger estate would combine composition, process, performance, and packaging claims, supported by comparative data against conventional bases.

How strong is the Migergot patent estate?

Migergot is a legacy small-molecule product with no meaningful biologic exclusivity barrier. The principal intellectual-property risk is likely to arise from formulation or process patents filed for a modernized product rather than from the original active ingredients.

IP category	Commercial relevance
Active-ingredient composition	Low. Ergotamine tartrate and caffeine are long-established compounds.
Original product patent	Likely expired or commercially irrelevant because of product age.
Orange Book-listed patents	Must be confirmed in the current FDA Orange Book entry. No current patent position should be assumed without a live listing.
Method-of-use patents	Potentially limited because migraine treatment uses are established.
Formulation patents	Potentially relevant for a new base, release profile, stability package, or patient-use system.
Manufacturing patents	Potentially relevant if the process solves content uniformity or degradation problems.
Regulatory exclusivity	Legacy exclusivity is expected to have expired.
Biosimilar protection	Not applicable. Migergot is a small-molecule drug, not a biologic.

The commercial patent strategy should focus on a differentiated formulation rather than attempting to reassert ownership over the active ingredients.

When does Migergot lose exclusivity and what is the Orange Book status?

Migergot is an old small-molecule product. Any original new-drug exclusivity and ordinary patent term associated with the legacy product would have expired long ago. Current exclusivity must be evaluated through the FDA Orange Book and FDA regulatory databases, not through the product’s historical launch date alone.[3]

The relevant questions are:

• Is the reference product currently listed as approved?
• Is it listed as marketed?
• Are any patents listed for the product?
• Is the product eligible to support an ANDA reference pathway?
• Has FDA identified the product as discontinued for reasons other than safety or effectiveness?
• Is there an equivalent marketed product available to establish practical competition?

The Orange Book distinguishes approval status from active commercial marketing. A product can remain historically approved while having limited or no current commercial availability. That distinction matters for a generic or reformulation program.[3]

What generic entry risks exist for Migergot?

Generic entry would not face a biosimilar approval process. A conventional equivalent would likely be evaluated through an ANDA if a suitable reference-product pathway remains available. A differentiated product with a new formulation, new excipient system, or new delivery performance may require a 505(b)(2) application instead.

ANDA strategy

An ANDA strategy would seek to demonstrate sameness in:

• Active ingredients
• Strength
• Dosage form
• Route of administration
• Conditions of use
• Quality attributes
• Bioequivalence or other applicable equivalence standards

For a rectal suppository, conventional oral bioequivalence assumptions may not apply. FDA may focus on product quality, in vitro release, local and systemic exposure, and comparative performance depending on the reference product and regulatory precedent.

505(b)(2) strategy

A 505(b)(2) route may be more attractive when the product has:

• A new suppository base
• A changed release profile
• Improved stability
• New packaging
• A different excipient system
• A new administration or handling advantage

A 505(b)(2) application can support a differentiated product but may trigger patent-certification and exclusivity considerations linked to the listed drug. Any Paragraph IV strategy would depend on the current Orange Book listing and the patents, if any, associated with the relevant reference product.

Which companies could challenge or compete with Migergot?

The competitive landscape is broader than direct ergotamine suppository competition. Migergot competes with oral triptans, nonoral triptans, dihydroergotamine products, gepants, and over-the-counter analgesic combinations.

Competitor category	Examples	Competitive effect
Oral triptans	Sumatriptan, rizatriptan, eletriptan	Strong substitution when patients can take oral medication
Nonoral triptans	Nasal or injectable sumatriptan, injectable or nasal zolmitriptan	Compete directly for patients with nausea or vomiting
Dihydroergotamine	Nasal and injectable products	Competes within the ergot class
Gepants	Ubrogepant, rimegepant, zavegepant	Offer non-ergot acute migraine treatment
OTC analgesics	Acetaminophen, NSAIDs, combination products	Compete in lower-severity attacks
Compounded rectal products	Pharmacy-compounded alternatives	May compete when commercial suppository access is limited

The most credible commercial challenger is a manufacturer with existing suppository capabilities, controlled-substance or potent-API handling experience, migraine distribution, and access to neurology and specialty-pharmacy channels.

What manufacturing and excipient barriers affect Migergot?

The key manufacturing barrier is not the complexity of the active ingredients. It is consistent delivery of a low-dose potent alkaloid from a physically stable rectal unit.

Critical manufacturing controls

A commercial process should control:

• Active-ingredient particle size
• Blend uniformity
• Base temperature
• Drug suspension viscosity
• Fill rate
• Mold temperature
• Cooling profile
• Unit weight
• Assay and content uniformity
• Suppository hardness
• Melting or softening behavior
• Packaging seal integrity

Ergotamine handling may also require appropriate containment and occupational controls because of the pharmacological potency of ergot alkaloids.

Supply-chain risks

Potential supply risks include:

• Limited suppliers for pharmaceutical-grade ergotamine tartrate
• Variability in natural-source or fermentation-derived intermediates
• Specialty suppository-base availability
• Regional differences in excipient compendial status
• Packaging-material shortages
• Small commercial batch sizes
• High testing costs relative to market volume

A dual-source strategy for the base and packaging is commercially preferable. The active ingredient may be the more difficult component to qualify because the supplier pool can be narrower than for standard excipients.

What commercial opportunities exist for a Migergot excipient program?

The strongest opportunities are product improvements that address practical limitations of suppository use.

Lower-leakage formulation

A high-performance base could reduce leakage, improve retention, and provide more predictable melting. This would support differentiation against older suppository products and compounded alternatives.

Heat-stable formulation

A formulation with improved resistance to deformation during shipping and storage could reduce product loss in warm climates. The formulation must retain acceptable release at body temperature.

Improved patient handling

Potential opportunities include:

• Peelable unit-dose packaging
• Reduced wrapper adhesion
• Clear administration orientation
• Less odor and staining
• Improved insertion characteristics
• Packaging suitable for discreet carrying

Packaging changes can have commercial value even when they do not alter the drug formulation.

Pediatric or special-population development

Ergotamine carries important safety and contraindication considerations, limiting the opportunity for broad pediatric expansion. A targeted population strategy would require regulatory and clinical support rather than relying on excipient changes alone.

Combination or rescue positioning

A rectal ergotamine-caffeine product could be positioned as a rescue option for patients unable to tolerate oral therapy. The market opportunity would depend on current treatment guidelines, safety labeling, prescriber acceptance, and reliable product availability.

What FDA regulatory issues apply to a Migergot reformulation?

FDA review would focus on product quality, clinical pharmacology, safety, and the relevance of the proposed formulation change. The regulatory pathway would depend on whether the applicant is pursuing a therapeutically equivalent generic or a clinically differentiated product.[3,4]

Key regulatory workstreams include:

1. Establishing the reference product and regulatory pathway.
2. Characterizing the active ingredients and excipient compatibility.
3. Developing a discriminatory in vitro release method.
4. Demonstrating assay and content uniformity.
5. Conducting forced-degradation studies.
6. Completing accelerated and long-term stability studies.
7. Evaluating container-closure integrity.
8. Assessing local tolerability.
9. Determining whether pharmacokinetic or comparative clinical studies are required.
10. Preparing patent certifications under the applicable pathway.

Because the product is a suppository, the development package should not rely only on dissolution data designed for oral dosage forms. Rectal performance, melting behavior, drug release, and systemic exposure must be evaluated as an integrated product-quality package.

What revenue exposure does Migergot create?

Standalone revenue exposure cannot be inferred reliably from historical product existence. The commercial opportunity depends on current prescription volume, product availability, reimbursement, competing acute migraine therapies, and the number of patients who need a nonoral option.

The product has potential value in a focused market because:

• The dosage form addresses vomiting and oral-treatment failure.
• The active ingredients are established and inexpensive relative to newer migraine agents.
• A reliable commercial product could displace compounded alternatives.
• A differentiated excipient and packaging platform could support lifecycle management.

The constraints are substantial:

• Ergotamine has significant contraindications and drug-interaction limitations.
• Newer migraine medicines have expanded treatment choice.
• Rectal administration limits broad consumer adoption.
• Manufacturing volumes may be modest.
• Payer coverage may favor newer branded or generic alternatives.

The best commercial model is likely a niche prescription product with dependable supply, specialty distribution, and a clearly defined use in patients who cannot use oral therapy.

Key takeaways

• Migergot is a legacy ergotamine tartrate and caffeine rectal suppository.
• The primary formulation opportunity is a stable, low-leakage, patient-acceptable suppository base.
• Content uniformity is a central technical risk because ergotamine is present at a low dose and is pharmacologically potent.
• Original active-ingredient and legacy-product exclusivity barriers are expected to be expired.
• Current Orange Book status, marketing status, and patent listings must control any ANDA or 505(b)(2) strategy.
• Biosimilar risk is irrelevant because Migergot is a small-molecule product.
• A modern formulation patent estate should claim measurable stability, release, manufacturing, or packaging improvements.
• The commercial opportunity is a focused rescue-treatment market, not a broad replacement for newer migraine therapies.
• Manufacturing reliability and excipient supply may determine commercial success more than active-ingredient cost.

FAQs about Migergot excipients and market strategy

Can a new suppository base create patent protection for Migergot?

Yes, but the base should be tied to demonstrated technical performance, such as improved stability, release, mechanical strength, or reduced leakage. Claims directed only to routine excipient substitution may face validity and obviousness challenges.

Is cocoa butter the best excipient for a Migergot suppository?

Not necessarily. Cocoa butter can provide a familiar melting profile, but hard fats and semisynthetic triglycerides may offer better batch consistency, heat stability, and manufacturing control. The choice requires comparative release and stability data.

Could a polyethylene glycol suppository improve Migergot shelf life?

It could improve resistance to heat-related deformation and may provide a more robust physical dosage form. The tradeoffs include local tolerability, release behavior, hygroscopicity, and potential changes in patient acceptance.

Would a reformulated Migergot product qualify for three-year FDA exclusivity?

A new formulation may qualify for statutory exclusivity only if it meets the applicable legal requirements and contains a qualifying change supported by the regulatory submission. Excipient substitution alone does not guarantee exclusivity.

Can pharmacies compound an alternative to Migergot?

Compounding may be possible under applicable federal and state requirements, but a compounded product is not automatically therapeutically equivalent to an FDA-approved commercial suppository. Differences in base, potency uniformity, stability, packaging, and quality controls can affect substitution decisions.

References

1. U.S. Food and Drug Administration. (n.d.). Migergot: Ergotamine tartrate and caffeine suppository prescribing information. FDA labeling database.

2. National Library of Medicine. (n.d.). DailyMed: Migergot ergotamine tartrate and caffeine suppository. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA guidance and regulatory materials. https://www.fda.gov/drugs/development-resources/505b2-application-guidance-regulatory-information